PI3Kδ抑制剂INCB040093单用或联合JAK1抑制剂itacitinib治疗复发/难治性B细胞淋巴瘤的1期研究
这项1期剂量递增/扩展研究评估了选择性PI3Kδ抑制剂INCB040093单药或联合选择性JAK1抑制剂itacitinib在复发/难治性B细胞淋巴瘤成人患者中的安全性、疗效、药代动力学和药效学。共治疗114例患者(单药组49例,联合组72例,其中7例从单药组交叉至联合组)。推荐2期剂量为INCB040093 100 mg每日两次(单药)和INCB040093 100 mg每日两次联合itacitinib 300 mg每日一次(联合)。INCB040093在B细胞淋巴瘤中具有活性,联合itacitinib在特定亚型中显示出有前景的活性。
要点
- 推荐2期剂量:单药INCB040093 100 mg每日两次;联合itacitinib 300 mg每日一次。
- 滤泡性淋巴瘤单药缓解率63%(5/8);经典型霍奇金淋巴瘤联合组缓解率67%(14/21)vs 单药组29%(5/17)。
- 联合组3级及以上转氨酶升高较单药组少见。
核心结论
- INCB040093单用或联合itacitinib在本研究中耐受且具有活性,是特定复发/难治性B细胞淋巴瘤患者有前景的治疗策略。
研究设计与样本
- 1期剂量递增/扩展研究,评估INCB040093单药或联合itacitinib在复发/难治性B细胞淋巴瘤成人患者中的安全性、疗效、药代动力学和药效学。
- 共治疗114例患者:单药组49例,联合组72例(其中7例从单药组交叉至联合组)。
主要发现
- 单药组发生1例剂量限制性毒性(继发于胃弥漫性大B细胞淋巴瘤消退的胃肠道出血)。
- 单药组最常见严重不良事件为肺炎(n=5)和发热(n=4)。
- 联合组最常见严重不良事件为耶氏肺孢子菌肺炎(n=5)、非耶氏肺孢子菌肺炎(n=5)和发热(n=4)。
- 联合组3级及以上转氨酶升高较单药组少见。
- 经典型霍奇金淋巴瘤联合组缓解率67%(14/21)vs 单药组29%(5/17);非生发中心B细胞样弥漫性大B细胞淋巴瘤联合组缓解率31%(4/13)。
关键数值与推荐
- 推荐2期剂量:INCB040093 100 mg每日两次(单药);INCB040093 100 mg每日两次联合itacitinib 300 mg每日一次(联合)。
- 滤泡性淋巴瘤单药缓解率63%(5/8)。
- 经典型霍奇金淋巴瘤联合组缓解率67%(14/21)vs 单药组29%(5/17)。
- 非生发中心B细胞样弥漫性大B细胞淋巴瘤联合组缓解率31%(4/13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because both phosphatidylinositol 3-kinase δ (PI3Kδ) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3Kδ inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas. Final results are reported. Overall, 114 patients were treated (monotherapy, n = 49; combination therapy, n = 72 [7 patients crossed over from monotherapy to combination]). INCB040093 100 mg twice daily (monotherapy) and INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination) were the recommended phase 2 doses. One dose-limiting toxicity (gastrointestinal bleed secondary to gastric diffuse large B-cell lymphoma [DLBCL] regression) occurred with monotherapy. The most common serious adverse events with monotherapy were pneumonia (n = 5) and pyrexia (n = 4), and with combination Pneumocystis jiroveci pneumonia (n = 5), pneumonia (unrelated to P jiroveci; n = 5), and pyrexia (n = 4). Grade 3 or higher transaminase elevations were less common with combination. INCB040093 was active across the B-cell lymphomas; 63% of patients (5/8) with follicular lymphoma responded to monotherapy. Adding itacitinib provided promising activity in select subtypes, with responses of 67% (14/21) in classic Hodgkin lymphoma (vs 29% [5/17] with monotherapy) and 31% (4/13) in nongerminal center B-cell-like DLBCL. INCB040093 with/without itacitinib was tolerated and active in this study, and is a promising treatment strategy for patients with select R/R B-cell lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT01905813.
引用
- Phillips TJ, Forero-Torres A, Sher T, et al. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood. 2018. PMID: 29695516. doi:10.1182/blood-2017-10-812701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。